Stockscreener 앱 받기
223.43
2.01%
4.41
시간 외 거래:
222.03
-1.40
-0.63%
Abbvie Inc 주식(ABBV)의 최신 뉴스
DOJ Drops Challenge To AbbVie's $1.6B Break Fee Deduction - Law360
AbbVie stock price closes higher on Moody’s upgrade — what ABBV bulls and bears watch next - TechStock²
Lupin and AbbVie Announce Partnership to Develop and Commercialize Novel Oncology Drug to treat Hematological CancersLupin | Press Release - lupin.com
Earnings Scorecard: 22 out of 23 healthcare firms deliver EPS wins this week - Seeking Alpha
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next - TechStock²
AbbVie (ABBV) Receives a Buy from Guggenheim - The Globe and Mail
CVS Caremark Replaces Amgen And Eli Lilly's Branded Drugs, Expands Biosimilar Strategy For Weak Bone Disorder - Benzinga
AbbVie upgraded by Moody’s to A2 with stable outlook - Investing.com Nigeria
Bank of America Securities Keeps Their Hold Rating on AbbVie (ABBV) - The Globe and Mail
Cantor Fitzgerald reiterates Overweight rating on AbbVie stock - Investing.com
Evercore ISI Group Lowers Price Target for AbbVie (ABBV) to $228 - GuruFocus
(02/06/26) Top Picks 2026: AbbVie Inc. (ABBV) - moneyshow.com
AbbVie Earnings Call: New Growth Engines Take Lead - The Globe and Mail
AbbVie stock ticks higher after hours as traders digest 2026 outlook after Rinvoq miss - TechStock²
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Boston Scientific (BSX) - The Globe and Mail
Earnings roundup: AbbVie angst, a bifurcated vaccine market and Bristol Myers’ waiting game - BioPharma Dive
Evercore ISI Adjusts Price Target on AbbVie to $228 From $232, Maintains Outperform Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on AbbVie to $240 From $223, Maintains Neutral Rating - marketscreener.com
AbbVie's Prognosis: The February Dip Looks Like a Buy Signal - Finviz
AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal - The Globe and Mail
AbbVie (ABBV) Receives a Neutral Rating as UBS Lowers Price Targ - GuruFocus
UBS Adjusts AbbVie Price Target to $230 From $240, Maintains Neutral Rating - marketscreener.com
AbbVie Submits Regulatory Applications for Rinvoq in Patients with Vitiligo - Contract Pharma
AbbVie: The Market Is Getting It Wrong - Seeking Alpha
AbbVie Inc. (NYSE:ABBV) Q4 2025 Earnings Call Transcript - Insider Monkey
AbbVie shares slide on perceived Humira reliance - The Pharma Letter
AbbVie Shares Fall as Wall Street Focuses on Filler Weakness - The Business of Fashion
ABBV Q4 Deep Dive: Immunology and Neuroscience Growth Offset Aesthetics Softness and Pricing Headwinds - Finviz
Street View: AbbVie's strong drug pipeline sets it up well for long‑term growth - TradingView
AbbVie: Skyrizi And Rinvoq Growth Isn't Everything But It's A Lot (NYSE:ABBV) - Seeking Alpha
AbbVie Earnings: Skyrizi Holds Steady Share Despite Competition - morningstar.com
AbbVie Inc. (ABBV) Shares Slide as Revenue Beat and Raised 2026 Outlook Fail to Stem Sell-Off - AlphaStreet News -
Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy - TipRanks
AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat '26 View - The Globe and Mail
AbbVie Q4 Earnings Call Highlights - Yahoo Finance
AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise (ABBV) - Seeking Alpha
AbbVie Q4 Earnings Review: I May Have Just Made A Huge Mistake (NYSE:ABBV) - Seeking Alpha
AbbVie’s Deal Focus Is Not Just Early-Stage Assets - Citeline News & Insights
ABBV AbbVie Inc. Feb 2026 Evercore Maintains Outperform, PT lowered to $228 - Meyka
AbbVie Inc (ABBV) Q4 2025 Earnings Call Highlights: Record Reven - GuruFocus
AMD, AbbVie, Boston Scientific, Eli Lilly, MP, Super Micro, Palantir, and More Movers - Barron's
AbbVie forecasts upbeat 2026 profit, but shares fall on key drug’s sales miss - WTVB
AbbVie’s Rinvoq Vitiligo Bid Raises Questions On Growth And Valuation - Yahoo Finance
AbbVie's Immunology Fortress Can’t Hide Cracks In Diversification (Downgrade) (NYSE:ABBV) - Seeking Alpha
AbbVie Buy Thesis Anchored by Robust Immunology Momentum, Neurology Upside, and Long-Term IBD Defense - TipRanks
AbbVie stock drops after Rinvoq sales miss, even as 2026 profit forecast tops estimates - TechStock²
AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. - Barron's
AbbVie forecasts 9.5% sales growth in 2026 amid blockbuster launches and pipeline momentum - MSN
AbbVie stock slides as investors focus on weakness in the aesthetics business - Crain's Chicago Business
AbbVie nears five-month low as Humira drives Q4 beat, not Rinvoq - Seeking Alpha
AMD, AbbVie, Lilly, Boston Scientific, MP Materials, Super Micro, Silicon Labs, Uber, and More Movers - Barron's
AbbVie forecasts upbeat 2026 profit, but shares fall on key drug's sales miss - marketscreener.com
Boston Scientific, AbbVie Beat Quarterly Views; Shares Slump Amid Weakness in Certain Segments - marketscreener.com
Eli Lilly, Novo Nordisk, AbbVie: Pharma earnings roundup - Yahoo Finance
ABBV Forecasts Revenue Boost with Favorable Currency Impact - GuruFocus
Earnings call transcript: AbbVie Q4 2025 beats earnings estimates, stock dips - Investing.com
AbbVie's (ABBV) Growth Prospects Show Strong Momentum - GuruFocus
AbbVie's (ABBV) Anticipated Q1 Revenue Falls Short of Market Exp - GuruFocus
AbbVie Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
AbbVie Raises 2026 Earnings Forecast as Botox Sales Rebound - bloomberg.com
AbbVie (ABBV) Stock: Slides 6.5% Despite Strong Revenue Growth and 2026 Outlook - CoinCentral
AbbVie (ABBV) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
AbbVie Q4 Adjusted Earnings, Revenue Rise; 2026 Adjusted Earnings Guidance Issued - marketscreener.com
These Stocks Are Today’s Movers: AMD, Eli Lilly, AbbVie, Uber, Super Micro, Enphase, Boston Scientific, and More - Barron's
1.82%
자본화:
|
볼륨(24시간):